The distinction begins with chemistry. Ashwagandha’s bioactivity is dominated by steroidal lactones called withanolides, but the withanolide profile differs sharply between organs. Comparative HPLC and UHPLC–MS/MS analyses show that leaves accumulate high levels of withaferin A and related epoxide-bearing withanolides, compounds with potent cytotoxic and anti-inflammatory properties. Roots, by contrast, are relatively enriched in withanolide A, withanolide D, and glycowithanolides, the marker compounds used in pharmacopoeial monographs and standardized commercial root extracts. In chemotype studies such as the variety Poshita, withaferin A peaks in field-grown leaves while withanolide A predominates in roots across multiple chemotypes, establishing a consistent gradient between the more cytotoxic leaf chemistry and the so-called tonic-type root chemistry.

That gradient maps onto a long history of differentiated use. Classical Ayurvedic texts describe ashwagandha primarily as a root-based Rasayana, a rejuvenating tonic prescribed as a powder with milk or ghee for stress, debility, insomnia, and neuromuscular disorders. The leaf appears only sparsely in the classical compendia but features prominently in regional and tribal ethnomedicine across India, where it is applied as pastes, poultices, and decoctions for painful swellings, wounds, boils, scorpion stings, and dental pain, and occasionally ingested for fever and metabolic complaints. In other words, tradition itself drew a line between the root as a systemic tonic and the leaf as a more localized, indication-specific remedy, a historical differentiation of expected benefit–risk profiles that modern science is now rediscovering.

Preclinical pharmacology reflects both shared and distinct activities. Root extracts show robust anti-stress, anxiolytic, anti-inflammatory, cardioprotective, and neuroprotective effects in rodent models, mechanisms linked to modulation of the hypothalamic–pituitary–adrenal axis, GABAergic and serotonergic signaling, and the NF-κB and Nrf2 pathways. Leaf extracts, richer in withaferin A and other electrophilic withanolides, display striking anticancer, immunomodulatory, and neuroprotective activity in vitro and in selected animal models, including selective killing of tumor cells and inhibition of NF-κB and STAT3 signaling. In some comparative experiments leaf preparations match or exceed root extracts on antioxidant and antitumor endpoints, but these studies typically employ higher withaferin A exposures over short durations, leaving the translational safety margins for chronic oral use in humans undefined.

The human evidence base is even more lopsided. Nearly all controlled clinical data derive from root extracts, typically at doses of 240 to 600 milligrams per day, and randomized double-blind placebo-controlled trials in adults with stress, anxiety, or poor sleep consistently report improvements in perceived stress, anxiety scales, sleep quality, and cortisol, with favorable tolerability over 6 to 12 weeks. A 12-month open-label study of a standardized root extract at 600 milligrams per day found no serious adverse drug reactions and no signal for cumulative hepatic, renal, thyroid, or hematologic toxicity, and a systematic review covering 30 clinical trials of root preparations reported no serious adverse events across indications ranging from chronic stress to rheumatoid arthritis and male infertility.

Leaf-specific human data are minimal but revealing. A Phase I open-label trial of a pharmaceutical-grade leaf extract known as RH324 in patients with advanced non-small cell lung cancer reported tolerability and preliminary disease stabilization over 28 days, while a separate Phase I study of a leaf-derived preparation in osteosarcoma patients recorded dose-dependent liver enzyme elevations in five of eleven participants. A small number of randomized trials have tested combined root-and-leaf aqueous extracts for chronic stress and resistance training, but these remain limited. The review’s authors stress that this sparse record does not prove the leaf is inherently unsafe; rather, the leaf evidence is insufficient for chronic systemic use, a critical distinction that much of the current regulatory debate has blurred.

Complicating the picture further is adulteration. The US Botanical Adulterants Prevention Program has documented frequent detection of leaf material in commercial products labeled as root or root-only extract, driven by economics: leaves are cheaper, renewable, and richer in withaferin A. Crucially, the program warns that assays based solely on total withanolides cannot distinguish root from leaf, since withanolides occur throughout the plant. Reliable authentication requires orthogonal methods combining HPTLC or HPLC fingerprinting, targeted quantification of withaferin A and quercetin-related metabolites, and DNA-based tools. This matters because some of the toxicological signal in European risk evaluations derives from studies on leaf or whole-plant preparations rather than authenticated root.

The regulatory consequences have been dramatic. In 2020, a literature-based risk assessment by the Technical University of Denmark concluded that a safe intake level for ashwagandha in supplements could not be established, citing potential thyroid and sex hormone effects and possible abortifacient properties, prompting Denmark to ban ashwagandha-containing supplements from 2023. Independent critiques argue the assessment over-weighted limited animal and case-report data, relied on low-quality sources, and conflated root with leaf and whole-plant preparations while overlooking the broader clinical safety dataset on standardized root extracts. Subsequent evaluations by the Dutch RIVM, Germany’s BfR, France’s ANSES, and the UK Food Standards Agency have flagged hepatotoxicity, thyroid, and reproductive concerns, even while acknowledging that much of the adverse-event literature involves products of uncertain composition and plant part.

Pharmacovigilance adds another layer of ambiguity. Published case reports of liver injury in ashwagandha users describe products that were never analytically characterized for plant part, and causality assessments using the RUCAM method reached only possible or probable scores, never definite. One research group has hypothesized that undeclared leaf adulteration, with its substantially higher withanone and withaferin A content, could contribute to hepatotoxicity, providing a plausible mechanistic basis for the case clusters. If some European hepatotoxicity reports in fact reflect exposure to unlabeled leaf or whole-plant material sold as root, then the central regulatory problem is quality and authenticity rather than plant identity alone, and plant-part-agnostic risk assessments risk punishing the wrong ingredient.

The review’s prescriptions are concrete. Monographs and guidance should define ashwagandha for internal use as root or root extract unless leaf or aerial parts are explicitly declared, with separate dossiers and safety data required for leaf products. Regulators should mandate validated orthogonal authentication methods in manufacturing release and market surveillance, treat undeclared aerial-part content as adulteration, and consider a dose-based framework for leaf anchored to withaferin A limitation, analogous to thresholds set for pyrrolizidine alkaloids, once adequate human pharmacokinetic and dose-escalation data exist to derive a safe exposure level. Priority research needs include comparative randomized trials of authenticated root, leaf, and whole-plant extracts with matched chemotyping, comprehensive hepatic, thyroid, and reproductive safety studies for leaf preparations, and a plant-part-stratified meta-analysis of adverse events across all published trials. Until such data arrive, the authors conclude, authenticated root remains the best-characterized material for systemic use, and the case for treating ashwagandha as a plant-part-specific medicine, not a generic herb, is now firmly on the scientific and regulatory agenda.

Subject of Research: Comparative safety, efficacy, and regulation of ashwagandha root versus leaf preparations

Article Title: Plant Part–Specific Differences in Ashwagandha (Withania somnifera): A Comparative Evaluation of Root and Leaf Evidence for Safety and Regulation

Article References: Dutta, A., & Gupta, J. B. (2026). Plant Part–Specific Differences in Ashwagandha ( Withania somnifera ): A Comparative Evaluation of Root and Leaf Evidence for Safety and Regulation. Food Science & Nutrition, 14(10), Article e72364. https://doi.org/10.1002/fsn3.72364

Image Credits: AI Generated

DOI: 10.1002/fsn3.72364

Keywords: ashwagandha, Withania somnifera, withanolides, withaferin A, herbal supplements, hepatotoxicity, adulteration, phytochemistry, regulation, Ayurveda, food safety, clinical trials

The scientific foundation of that leap rests on a remarkably rich phytochemical profile. Arjuna bark contains four major classes of bioactive compounds: triterpenoids including arjunic acid, arjunolic acid, arjunetin, arjungenin, and arjunglucosides; fifteen varieties of tannins, among them casuarinin and punicalagin; flavonoids such as luteolin, quercetin, kaempferol, and baicalein; and phenolic acids like gallic and ellagic acid. Together with minerals including copper, zinc, magnesium, and calcium, these constituents underpin a pharmacological portfolio spanning anti-tumoral, anti-inflammatory, antioxidant, antimicrobial, hypolipidaemic, wound-healing, cardioprotective, and anti-diabetic activities. But the review also reveals a crucial technical caveat: the chemistry is not uniform. Stem bark is the principal source of arjunic and arjunolic acids, while root bark yields distinct glycosides, and HPLC sampling across Indian geographic locations found substantial site-to-site variation in arjungenin and arjunic acid content. Extraction method matters too—alcoholic solvents efficiently pull out arjunic acid while hexane does not, and ultrasound-assisted extraction preserves more phenolics and flavonoids than conventional heating. Different solvents yielded only nine phytochemicals in common out of thirty identified compounds, meaning that two Arjuna products on a shelf may be chemically different medicines.

Nowhere is the molecular story more striking than in cancer research, where Arjuna’s compounds converge on a shared lethal strategy against malignant cells: mitochondrial, ROS-driven, caspase-mediated apoptosis. In non-small-cell lung cancer lines A549 and H460, arjunic acid triggers apoptotic body formation, PARP cleavage, and a JNK-dependent endoplasmic reticulum stress pathway involving IRE1α, ATF4, and CHOP—when researchers blocked JNK with the inhibitor SP600125, the cytotoxicity vanished, confirming the pathway’s centrality. Casuarinin, a hydrolysable tannin from the bark, tells an equally elegant story of molecular flexibility. In A549 lung cancer cells it induces G0/G1 cell-cycle arrest through p53 upregulation and p21/WAF1 induction, yet in MCF-7 breast cancer cells it elevates p21 without touching p53, reaching the same endpoint through a different door. The compound also activates the extrinsic Fas/FasL and caspase-8 pathway and shows anti-herpes activity against HSV-2 by disrupting viral glycoproteins C and D, blocking viral entry at concentrations with no toxicity to kidney cells.

Animal models have pushed the evidence beyond the dish. Arjunolic acid reduced tumor growth in Ehrlich ascites carcinoma mice by suppressing TGF-β1 signaling, restoring immune balance, and activating caspase-3, while ethanolic bark extract prolonged survival in Dalton’s lymphoma mice by 60 to 87.5 percent depending on dose and extended lifespan by roughly 35 percent in a solid tumor model. In a chemoprevention twist, oral administration of the extract at 500 milligrams per kilogram reduced tumor incidence and burden in hamsters exposed to the carcinogen DMBA, normalizing antioxidant status along the way. The most futuristic branch of this work involves nano-engineering: self-assembled arjunolic acid forms liposome-like vesicles that selectively enter cancer cells and kill them through a TNF-α-driven, ROS-dependent pathway; biosynthesized silver and selenium nanoparticles from the bark showed potent cytotoxicity against HepG2, PC3, and MCF-7 cells while sparing normal Vero cells; and copper-silver multi-walled carbon nanotube hybrids extended the approach across multiple cancer lines. The honest limitation, the review stresses, is that none of these nano-formulations has been tested for pharmacokinetics, toxicity, or safety in living organisms, and no human cancer trial of Arjuna exists at all.

Cardiovascular protection, by contrast, is where Arjuna’s evidence is strongest—and where its traditional reputation as a heart remedy finds its most concrete modern support. Across three distinct toxic-injury models, the extract and its constituents consistently shield cardiomyocytes through antioxidant and anti-apoptotic mechanisms. Against cobalt chloride-induced hypoxia in H9c2 heart cells, pretreatment restored viability and rebalanced the Bax/Bcl-2 apoptotic switch. Against doxorubicin, the chemotherapy drug whose cardiotoxicity limits its clinical use, arjunolic acid suppressed p38/JNK-driven Bax translocation, preserved mitochondrial membrane potential, and prevented cytochrome c release—a finding that raises the possibility of Arjuna as a cardioprotective adjunct for patients undergoing chemotherapy. Against isoproterenol-induced myocardial necrosis, the extract elevated antioxidant enzymes and blocked JNK/c-jun signaling. Deeper mechanistic work revealed that arjunolic acid acts as a direct PPARδ agonist that also inhibits TAK1, blocking non-canonical TGF-β signaling to regress cardiac fibrosis—when researchers silenced PPARδ, the anti-fibrotic effect disappeared entirely. In atherosclerosis-prone ApoE-deficient mice, aqueous extract downregulated CD36, MMP-9, VCAM-1, and ICAM-1 while activating cholesterol-efflux regulators PPAR-γ and LXR-α, reducing plaque burden with effects the study reported as comparable to atorvastatin, though from a single animal experiment rather than a head-to-head trial.

The protective reach extends well beyond the heart. Arjunolic acid guards the liver against acetaminophen overdose by inhibiting CYP2E1, the enzyme that converts the painkiller into its toxic metabolite NAPQI, and against cadmium, arsenic, and fluoride by restoring glutathione balance and antioxidant enzymes. In the kidney, it counters cisplatin nephrotoxicity by suppressing NF-κB, TGF-β, and caspase cascades, while aqueous extract reduces calcium oxalate crystallization and crystal adhesion to renal epithelial cells—the underlying process of kidney stones—with four novel antiurolithiatic proteins recently identified from the bark. Neuroprotection is emerging too: in rat stroke models the extract reduced infarct volume and preserved blood-brain barrier tight-junction proteins, and at simulated high altitude it reversed hypobaric hypoxia-induced renal and cerebrovascular damage through an atrial natriuretic peptide-mediated mechanism. In diabetes models, Arjuna works on both ends of the metabolic problem—boosting insulin availability and IRS-1/PI3K/Akt signaling while directly inhibiting DPP-IV with activity close to the drug sitagliptin, plus α-amylase and α-glucosidase to blunt post-meal glucose spikes, all while protecting the pancreas, retina, and heart from hyperglycemic injury through AMPK-mTOR-HO-1 autophagy and NF-κB/MAPK suppression.

Human clinical data, though limited, is genuinely encouraging and concentrated in cardiology. A double-blind trial in 116 coronary artery disease patients found that 500 milligrams of extract twice daily for three to six months lowered triglycerides and VLDL cholesterol more effectively than atorvastatin alone while suppressing TNF-α and IL-6 and raising IL-10. A long-term observational study followed 35 chronic CAD patients taking the extract alongside standard therapy for four to five years with no adverse effects on blood, liver, or kidney parameters, no hospitalizations, and no deaths—though without a randomized control group it cannot isolate the herb’s contribution. In heart failure, the results diverge instructively: a tiny 12-patient trial in severe refractory cases reported improved ejection fractions sustained over 28 months, but a larger, better-powered 100-patient trial found no ejection-fraction benefit, instead showing gains in exercise tolerance, quality-of-life scores, and red-cell antioxidant markers. Additional trials reported reduced ischemic mitral regurgitation after heart attack, improved endothelial function in chronic smokers, improved venous clinical severity in chronic venous insufficiency, and—remarkably—fasting blood sugar and HbA1c reductions comparable to sitagliptin when combined with metformin in type 2 diabetes. A dermatological study even found that a 0.25 percent extract cream cut transepidermal water loss by 46 percent and quadrupled skin moisturization, opening a cosmeceutical frontier.

Food scientists are already translating this pharmacology into edible formats. Microencapsulated Arjuna extract blended into a vanilla chocolate milk drink significantly reduced triglycerides, total cholesterol, LDL, and VLDL in hypercholesterolemic rats over a 60-day trial while preserving the beverage’s flavor and sensory properties. Seven percent ethanolic bark extract extended the shelf life of ghee several-fold in accelerated oxidation testing, and graded concentrations of the extract in goat meat batter reduced lipid oxidation and spoilage organisms over nine days of storage. In aquaculture, dietary bark powder at 10 grams per kilogram of feed enhanced immune markers in rohu fish over 90 days. Arjuna gum itself has emerged as a natural biopolymer for pH-responsive microbeads and controlled-release gels, and calcium-alginate edible films containing the extract improved the oxidative and microbial stability of chevon sausages—positioning the tree as both ingredient and packaging technology.

Safety data are reassuring but incomplete, and the review is candid about the gaps. Short-term toxicity is low: hydroalcoholic bark extract showed no mortality at 2,000 milligrams per kilogram and no harmful effects at 1,000 milligrams per kilogram daily for 28 days, and both hydroalcoholic and methanolic bark extracts were negative in Ames and chromosomal aberration tests. Yet a methanolic leaf extract had an LD50 of 900 milligrams per kilogram, and alcoholic bark extract reduced testicular steroidogenic activity and testosterone in male rats after 21 days—findings that cannot be extrapolated across preparations. Pharmacokinetic studies show the extracts inhibit CYP3A4, CYP2D6, and CYP2C9 in vitro, with whole-extract composition, not individual triterpenoids, driving the interaction risk, and a nanosuspension formulation boosted oral bioavailability 1.33-fold. The path forward, the authors argue, requires larger multi-center placebo-controlled trials with standardized, chemically characterized formulations, harmonized endpoints, nanotechnology and microencapsulation for bioavailability, and multiomic approaches enabling precision nutrition. If those pieces come together, a tree worshipped in ancient Sanskrit medical texts may finally earn its place not just in tradition, but in the evidence-based architecture of modern food and health.

Subject of Research: Phytochemistry, pharmacology, clinical evidence, and nutraceutical applications of Terminalia arjuna bark

Article Title: Harnessing Terminalia arjuna in Next Generation Phytomedicine: Cutting Edge Nutraceutical Trends Shaping Food and Health

Article References: Banerjee, I., Nazeerulla, F., Paul, M. K., Bhutia, S. K., Basu, D., & Mukhopadhyay, S. (2026). Harnessing Terminalia arjuna in Next Generation Phytomedicine: Cutting Edge Nutraceutical Trends Shaping Food and Health. Food Science & Nutrition, 14(10), Article e72352. https://doi.org/10.1002/fsn3.72352

Image Credits: AI Generated

DOI: 10.1002/fsn3.72352

Keywords: Terminalia arjuna, Ayurveda, phytomedicine, nutraceuticals, cardioprotection, arjunolic acid, arjunic acid, casuarinin, functional foods, antioxidants, nanoparticles, clinical trials

The choice of these two botanicals was anything but arbitrary. Triphala, whose name literally means three fruits, is a classical formulation combining the dried fruits of Amalaki (Emblica officinalis), Bibhitaki (Terminalia bellirica) and Haritaki (Terminalia chebula). It has long been prized in Ayurveda as a rejuvenating Rasayana, credited with benefits ranging from digestive support to eye health, and modern phytochemistry has attributed much of its activity to a rich arsenal of polyphenols, tannins, gallic acid and vitamin C. Punarnava, meanwhile, derives its name from the Sanskrit for renewing or reviving, and the creeping herb Boerhavia diffusa has been used traditionally to treat inflammation, liver disorders and urinary complaints. Despite this long history of parallel use, the two remedies had rarely been evaluated head to head under identical analytical conditions, a gap the Indian team set out to close.

A key methodological innovation of the study lies in how the plant material was extracted. Rather than relying on conventional maceration or Soxhlet techniques, which can be slow and thermally punishing, the researchers employed microwave-assisted extraction, or MAE, using a hydroalcoholic solvent mixture of 70 percent ethanol and 30 percent water. The extraction was performed at 200 watts and 50 degrees Celsius for just 18 minutes. This approach exploits the ability of microwave energy to heat solvent and plant cell moisture from within, rupturing cell walls rapidly and liberating bioactive compounds efficiently while minimizing degradation of heat-sensitive molecules such as phenolics and tannins. The ethanol water blend was chosen deliberately: water extracts highly polar constituents, ethanol captures moderately polar phenolics, and the combination maximizes the diversity of compounds recovered from both formulations.

With extracts in hand, the team assembled an unusually comprehensive battery of antioxidant tests, seven in total, each probing a different chemical facet of radical-scavenging capacity. The DPPH assay measures the ability of antioxidants to neutralize a stable synthetic nitrogen radical, providing a rapid readout of hydrogen-donating capacity. The ABTS assay extends this logic to both hydrophilic and lipophilic antioxidants by generating a green chromophore that decolorizes when reduced. The FRAP and CUPRAC assays assess reducing power, quantifying the capacity to convert ferric ions to ferrous ions and cupric ions to cuprous ions, respectively, which serves as a proxy for total antioxidant potential. Complementing these four, the researchers measured scavenging of nitric oxide, hydroxyl radical and superoxide radical, three reactive species with direct biological relevance, since these molecules are generated in living tissues during inflammation and contribute to oxidative damage of lipids, proteins and DNA.

Across the DPPH, ABTS, FRAP and CUPRAC assays, Triphala consistently outperformed Punarnava, achieving lower IC50 or EC50 values, meaning smaller concentrations of extract were needed to produce a half-maximal effect. This concentration-dependent superiority is chemically plausible: the three fruits of Triphala are famously dense in gallic acid, ellagic acid, chebulinic acid and ascorbic acid, compounds whose structures are optimized for electron donation and radical stabilization. The result positions Triphala as a broad-spectrum antioxidant capable of intercepting multiple classes of reactive oxygen and nitrogen species, the molecular vandals implicated in oxidative stress, a state now associated with aging, cardiovascular disease, neurodegeneration, diabetes and chronic inflammatory conditions.

The anti-inflammatory half of the investigation used two complementary assays that model different mechanisms of tissue protection. The protein denaturation assay examines whether an extract can prevent the structural unfolding of proteins, such as bovine serum albumin, under stress, since protein denaturation is thought to trigger autoimmune responses and inflammation in vivo, a mechanism implicated in rheumatic diseases. The proteinase inhibition assay, by contrast, tests the capacity to block proteolytic enzymes such as trypsin, which are released during inflammatory episodes and contribute to tissue destruction. Non-steroidal anti-inflammatory drugs, the clinical standard, are known to act partly through these mechanisms, making the assays a meaningful benchmark for botanical candidates.

Here the rankings flipped. Punarnava exhibited stronger anti-inflammatory activity than Triphala in both the protein denaturation and proteinase inhibition assays, again in a concentration-dependent fashion. The researchers interpret this as evidence that Boerhavia diffusa contains constituents particularly adept at stabilizing protein structure and restraining proteolytic cascades. The plant is known to harbor alkaloids such as punarnavine, along with flavonoids, lignans and ecdysteroids, any of which could underlie this protective behavior, although the present study did not attempt compound-level attribution. What matters from a pharmacological standpoint is the pattern: the two botanicals are not redundant but complementary, each excelling where the other is merely competent.

That complementarity is the study’s most intriguing implication. Oxidative stress and inflammation are deeply intertwined pathologies: reactive oxygen species activate inflammatory signaling pathways, including those involving tumor necrosis factor-alpha, and inflammatory cells in turn generate more free radicals, creating a self-amplifying loop. A therapeutic strategy that pairs a potent antioxidant with a potent anti-inflammatory agent could theoretically interrupt this loop at both ends. The authors suggest that Triphala and Punarnava, used together, could serve as natural sources for the development of new complementary therapeutic modalities for managing diseases and disorders in which both oxidative damage and inflammation play driving roles. Such conditions include, plausibly, metabolic syndrome, arthritis and ocular disorders, where both mechanisms converge.

Important caveats temper the enthusiasm, and the authors are careful to acknowledge them implicitly by framing the work as in vitro. Test-tube assays demonstrate chemical activity but say nothing about whether the active compounds survive digestion, reach target tissues in sufficient concentrations, or exert comparable effects in the complexity of a living organism. Bioavailability, metabolism, dosing and safety in humans all remain open questions that will require animal studies and, ultimately, controlled clinical trials. Nor did the study characterize the extracts’ full chemical fingerprints or isolate the specific molecules responsible for each activity. Nevertheless, by applying standardized, quantitative, concentration-dependent benchmarks to two venerable botanicals prepared with a modern extraction technology, the research provides a reproducible analytical foundation for that next phase. It transforms what has often been traditional assertion into testable hypothesis, and in doing so hands formulation scientists a provocative pairing: Triphala to quench the radicals, Punarnava to calm the inflammatory response, each doing what it demonstrably does best.

Subject of Research: Comparative in vitro evaluation of antioxidant and anti-inflammatory activities of Triphala and Punarnava extracts

Article Title: In vitro assessment of antioxidant and anti-inflammatory activities of Triphala and Punarnava: a comparative study

Article References: Makhijani, S., & Khobragade, D. (2026). In vitro assessment of antioxidant and anti-inflammatory activities of Triphala and Punarnava: a comparative study. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05580-3

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05580-3

Keywords: Triphala, Punarnava, Boerhavia diffusa, antioxidant activity, anti-inflammatory activity, microwave-assisted extraction, DPPH, ABTS, FRAP, CUPRAC, Ayurveda, in vitro study

The review describes L. aspera as an annual herb reaching 15 to 60 centimeters in height, distributed widely across tropical and subtropical Asia, including India, Bangladesh, Nepal, Malaysia, and Mauritius. Its taxonomic classification places it in the Lamiaceae family alongside mint and basil, and its vernacular names across Indian languages reflect deep cultural familiarity. The plant blooms white, sessile, zygomorphic flowers from August to September, and every part, from roots to seeds, has found a place in traditional healing. In Ayurveda and Siddha medicine, the whole plant is used as a carminative, antipyretic, antiseptic, anti-inflammatory, and anti-snake venom agent, treating conditions ranging from jaundice and dyspepsia to rheumatism and respiratory ailments.

What gives the plant its versatility is an unusually rich phytochemical inventory. The review identifies roughly sixty chemical compounds spanning multiple structural classes, including flavonoids, alkaloids, terpenoids, glycosides, sterols, phenolic compounds, and fatty acids. Notable constituents include the triterpenoids ursolic acid and oleanolic acid, the diterpenes leucasperones A and B and leucasperols A and B, isopimarane glycosides known as leucasperosides A, B, and C, and the oleanane-type triterpenoid lactone leucolactone isolated from the roots. Seed oil contains linoleic, oleic, palmitic, stearic, and linolenic acids, while leaf volatiles are dominated by alpha-farnesene, alpha-thujene, and menthol. Lignans such as nectandrin B and macelignan, along with long-chain aliphatic ketones and alcohols, round out a chemical repertoire that rivals many cultivated medicinal species.

The pharmacological evidence assembled by the authors is striking in its breadth. Antimicrobial studies show that dichloromethane leaf extracts inhibit pathogens including Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, and Candida albicans at minimum inhibitory concentrations between 75 and 425 micrograms per milliliter, while methanolic whole-plant extracts, rich in flavonoids and phenolics, produce broad inhibition zones against both Gram-positive and Gram-negative bacteria. Antioxidant assays reveal that leaf flavonoids scavenge DPPH radicals with an IC50 of just 9.25 micrograms per milliliter, outperforming the reference compound gallic acid at equivalent doses. Perhaps most intriguingly, recent work has used the plant’s phytochemicals as reducing and stabilizing agents to biosynthesize chitosan-zinc oxide nanocomposites, which achieved up to 88.19 percent ABTS radical scavenging, a result attributed to synergistic interactions between the nanoparticle surfaces, chitosan functional groups, and the plant’s phenolic compounds.

Anti-inflammatory findings are similarly compelling. Extracts of the whole plant reduced cytokine production in mouse macrophage cells by 24 to 39 percent, suppressing interleukin-1 beta, a key pro-inflammatory mediator, and aqueous leaf extracts inhibited heat-induced red blood cell membrane denaturation by 73.25 percent at 100 micrograms per milliliter, nearly matching the standard drug diclofenac. In diabetes models, aqueous leaf extracts lowered blood glucose in streptozotocin-induced diabetic rats to 98.35 milligrams per deciliter at 400 milligrams per kilogram, outperforming the reference drug glibenclamide in some comparisons, while methanolic extracts reduced serum glucose by up to 42.10 percent in glucose-loaded mice. Researchers attribute these effects partly to the substantial quantities of oleanolic and ursolic acid found throughout the genus.

The review also documents hepatoprotective activity across several liver injury models, with extracts protecting against damage induced by paracetamol, carbon tetrachloride, lead acetate, and d-galactosamine by normalizing liver enzymes, reducing lipid peroxidation, and elevating antioxidant defenses such as glutathione peroxidase and catalase. Cytotoxicity studies against breast cancer cell lines showed that flavonoid and alkaloid fractions inhibited MCF-7 cell growth with IC50 values of 247.56 and 236.45 micrograms per milliliter respectively, while dichloromethane and ethyl acetate extracts suppressed proliferation in triple-negative MDA-MB-231 cells at concentrations as low as 3 to 5 micrograms per milliliter, suggesting potential as a source of leads against aggressive cancers.

Beyond these headline activities, the plant demonstrated analgesic effects across six pain models in mice, with a 700 milligrams per kilogram dose reducing responses by up to 84.74 percent, alongside verified anthelmintic, antipyretic, anti-ulcer, anti-asthmatic, anti-psoriatic, and anti-obesity properties. One of the more striking findings concerns snakebite: a triterpenoid isolated from the methanolic extract, 1-hydroxytetratriacontane-4-one, showed potent antidote activity against spectacled cobra venom in mice, and chitosan-based nanoparticles loaded with the plant extract neutralized Indian cobra venom toxicity. As a larvicide, the isolated compound catechin killed mosquito larvae, and silver nanoparticles synthesized from leaf extracts showed strong activity against the dengue vector Aedes aegypti, positioning the weed as an inexpensive bioresource for vector control.

Safety data support the plant’s traditional standing. Acute and sub-acute toxicity studies conducted under OECD guidelines 423 and 425 found no lethality or adverse behavioral changes at doses up to 2,000 milligrams per kilogram across multiple extract types and animal models, establishing median lethal doses above that threshold. The plant has already entered commercial use in homeopathic preparations, notably L. aspera 30CH dilutions marketed for asthma, cough, jaundice, dysentery, and intermittent fevers, and mother tinctures valued for their antipyretic and antimicrobial qualities. Its nutraceutical profile, marked by favorable mineral content and negligible heavy metal contamination, further suggests applications in functional foods, while its essential oils show promise as eco-friendly biopesticides.

Yet the review’s authors are candid about the gaps that separate preclinical enthusiasm from clinical reality. Most pharmacological data derive from in vitro experiments and animal studies, human trials are scarce, and variations in plant parts, extraction methods, and experimental protocols complicate comparisons across studies. Chronic toxicity, reproductive safety, genotoxicity, pharmacokinetics, and herb-drug interactions remain essentially uncharacterized, and many studies use crude extracts without adequate phytochemical standardization. Overexploitation also threatens wild populations, prompting calls for tissue culture conservation, transgenic development, and metabolite enhancement. The authors argue that the path forward lies in isolating novel bioactive compounds, standardizing formulations, applying nanotechnology-based delivery systems, and ultimately conducting randomized clinical trials. If those steps succeed, a weed once dismissed from the margins of wastelands may yet earn a place in the modern pharmacopoeia.

Subject of Research: Phytochemistry, pharmacological activities, and clinical applications of the medicinal plant Leucas aspera

Article Title: A comprehensive review of the phytochemistry, pharmacological activities and clinical applications of Leucas aspera

Article References: Pathak, M., Gaba, V., & Joshi, B. C. (2026). A comprehensive review of the phytochemistry, pharmacological activities and clinical applications of Leucas aspera. Discover Chemistry, 3(1), Article 525. https://doi.org/10.1007/s44371-026-00971-4

Image Credits: AI Generated

DOI: 10.1007/s44371-026-00971-4

Keywords: Leucas aspera, phytochemistry, pharmacological activities, Dronapushpi, Ayurveda, antimicrobial, anti-inflammatory, antidiabetic, hepatoprotective, snake venom, larvicidal, natural products